Preoperative immune prognostic index predicts outcomes in esophageal cancer.

The immune prognostic index (ipi) effectively predicts prognosis and the benefit of postoperative chemotherapy in esophageal squamous cell carcinoma (ESCC) patients following minimally invasive esophagectomy (MIE). Patients with a low ipi demonstrated significantly better 5-year overall survival (OS) and disease-free survival (DFS) compared to those with a high ipi. Notably, adjuvant chemotherapy in stage III patients with a high ipi was associated with improved OS and DFS, marking ipi as a valuable prognostic tool.